INDIA MARKET LENS

Divi's Laboratories Limited (DIVISLAB): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Divi's Laboratories Limited, explained in plain English.

  • Divi's Laboratories Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • DIVISLAB closed at ₹11,180.50 on 20 November 2026.
  • Over the past year the shares are up 73.0%, trading between ₹5,647.50 and ₹11,824.00.
  • Reported fundamentals show return on equity of 20.13%, a net margin of 27.59%, debt to equity of 0.03.
  • Our Pulse grade checklist scores it A (96/100) across momentum, growth, profitability and safety on fixed thresholds.
  • Annualised volatility over the past year is 25.31% with a maximum drawdown of -12.37% and a beta of 0.61 against NIFTY 50.
  • Recent coverage: Pharma stocks under pressure; Laurus, Sai Life, Divi's slide up to 10%
  • Recent coverage: Divi's Laboratories Market Cap Crosses Rs 3 Lakh Crore: What Is Driving The Rally
  • Recent coverage: ICICI Bank, Divi's among 14 NSE 500 stocks hit new highs in Muhurat session

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Last traded values from 20 Nov 2026. Closed — weekend.

Divi's Laboratories Limited (DIVISLAB)

₹11,180.5

▲ 2.5 (+0.02%)

Price & volume

DIVISLAB price chart, 1Y range. 252 points from 2025-11-24 to 2026-11-20. Opens at 6,359, closes at 11,180.5, ranging between 5,821 and 11,565.5.6,0008,00010,000Nov-25Jan-26Mar-26May-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Strong momentum · 5/5
✓ Above 50-day avg✓ Above 200-day avgRSI 67.9 · healthyMACD positiveBollinger %B 71ADX 52.8 · strong trend

1M

+23.04%

3M

+30.46%

6M

+62.20%

1Y

+73.01%

Where it sits in its 52-week range

93%
₹5,821₹11,565.5

Below 52-week high

3.3%

92.1% above the low

Momentum read

Strong

5/5 checks passed

52-wk high

₹11,565.5

52-wk low

₹5,821

Market cap

₹2,96,807 Cr

P/E (trailing)

88.2

Dividend yield

—

ROE

20.13%

Profit margin

27.59%

Revenue growth

35.4%

Price / Book

16.48

Debt / Equity

0.03

EPS (TTM)

126.72

Book value

₹678.52

Beta

0.61

Pulse grade: A, 96 out of 100

Momentum

A
  • ✓Trading above 50-day average
  • ✓Trading above 200-day average
  • ✓RSI in healthy 45-70 zone
  • ✓Positive 3-month return

Growth

A
  • ✓Revenue growth above 12%
  • ✓Revenue growing above 5%
  • ✓Quarterly profits trending up

Profitability

A
  • ✓Return on equity above 18%
  • ✓Return on equity above 12%
  • ✓Profit margin above 12%

Safety

A
  • ✓Debt below 50
  • ✓Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹3,676 crore · net profit ₹1,127 crore · margin 30.7%

3,6760Jun 2025n/aSep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,884.9-0.79%-5.81%
DRREDDY1,390.2-0.76%-0.76%
CIPLA1,415-0.25%-7.59%
APOLLOHOSP9,200+5.29%0.00%
LUPIN2,014+0.76%-19.91%
AUROPHARMA1,799-0.37%-3.03%

DIVISLAB headlines

No DIVISLAB stories right now.

DIVISLAB filings & announcements

Reading the exchange…

DIVISLAB, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

25.31%

Sharpe ratio

2.12

Sortino ratio

3.83

Max drawdown

-12.37%

Daily VaR (95%)

-2.28%

CAGR (1Y)

76.22%

Return skew

0.93

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.